Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings

Celcuity, Inc. (NASDAQ:CELC) gapped down before the market opened on Friday following a dissappointing earnings announcement. The stock had previously closed at $86.60, but opened at $83.04. Celcuity shares last traded at $89.8930, with a volume of 239,349 shares changing hands.

The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.28). The company had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $4.42 million.

Key Stories Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Stifel Nicolaus maintained a Buy rating while lowering its price target from $175 to $150, implying substantial upside from the referenced price. Benzinga analyst rating coverage
• Positive Sentiment: Needham & Company also kept a Buy rating and reduced its target from $157 to $140, signaling that analysts still see meaningful potential in Celcuity despite the revisions. Benzinga analyst rating coverage
• Neutral Sentiment: Celcuity released its second-quarter 2026 results and provided a corporate update. Investors are reviewing management’s development and commercialization progress for its targeted cancer therapies. Celcuity second-quarter 2026 results and corporate update
• Negative Sentiment: Celcuity reported a second-quarter loss of $1.44 per share, wider than the consensus loss estimate of $1.16, while revenue of approximately $0.09 million fell far short of the $4.42 million estimate. The results prompted analysts to slash forecasts, increasing concern about commercialization timing and near-term financial performance. Celcuity analysts lower forecasts after second-quarter loss

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Craig Hallum reaffirmed a “buy” rating and issued a $178.00 price target on shares of Celcuity in a research report on Wednesday, July 15th. Citigroup reiterated an “outperform” rating on shares of Celcuity in a report on Wednesday, July 15th. Wall Street Zen cut Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Needham & Company LLC dropped their target price on shares of Celcuity from $157.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Guggenheim reiterated a “buy” rating on shares of Celcuity in a research note on Wednesday, June 3rd. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Celcuity presently has a consensus rating of “Moderate Buy” and an average target price of $153.64.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CELC. Avoro Capital Advisors LLC bought a new stake in Celcuity in the 4th quarter valued at $310,302,000. NEA Management Company LLC boosted its position in shares of Celcuity by 64.9% during the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock valued at $352,637,000 after acquiring an additional 1,391,300 shares in the last quarter. State Street Corp increased its stake in Celcuity by 126.6% in the fourth quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after acquiring an additional 914,887 shares during the period. UBS Group AG raised its position in Celcuity by 910.1% in the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock worth $42,211,000 after purchasing an additional 769,891 shares in the last quarter. Finally, Deerfield Management Company L.P. acquired a new position in Celcuity in the third quarter worth about $36,236,000. 63.33% of the stock is owned by institutional investors.

Celcuity Trading Up 4.0%

The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. The business’s 50 day simple moving average is $93.81 and its 200 day simple moving average is $108.56. The stock has a market cap of $4.39 billion, a P/E ratio of -23.10 and a beta of 0.20.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.